EISAI INC Company Profile

✉ Email this page to a colleague

EISAI INC has eleven approved drugs.

There are fourteen US patents protecting EISAI INC drugs.

There are three hundred and ten patent family members on EISAI INC drugs in forty-two countries and thirty-nine supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	LUSEDRA	fospropofol disodium	SOLUTION;INTRAVENOUS	022244-001	Dec 12, 2008		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No	9,006,256*PED	⤷ Sign Up			Y	⤷ Sign Up
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	022568-001	Jul 23, 2010	4,895,841	⤷ Sign Up
Eisai Inc	LUSEDRA	fospropofol disodium	SOLUTION;INTRAVENOUS	022244-001	Dec 12, 2008	6,204,257	⤷ Sign Up
Eisai Inc	ARICEPT	donepezil hydrochloride	TABLET;ORAL	020690-002	Nov 25, 1996	4,895,841	⤷ Sign Up
Eisai Inc	BANZEL	rufinamide	TABLET;ORAL	021911-003	Nov 14, 2008	6,740,669*PED	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	4 mg and 10 mg	➤ Subscribe	2019-02-13
➤ Subscribe	Tablets	100 mg, 200 mg and 400 mg	➤ Subscribe	2012-11-14
➤ Subscribe	Orally Disintegrating Tablets	5 mg and 10 mg	➤ Subscribe	2010-06-30
➤ Subscribe	Tablets	23 mg	➤ Subscribe	2013-07-09
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2014-06-16

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1087960	132011901976051	Italy	⤷ Sign Up	PRODUCT NAME: ERIBULINA(HALAVEN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/678/001-002, 20110317
1698623	PA2015039	Lithuania	⤷ Sign Up	PRODUCT NAME: LENVATINIBUM; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528
1087960	SPC026/2011	Ireland	⤷ Sign Up	SPC026/2011: 20111128, EXPIRES: 20240615
1415987	CA 2015 00053	Denmark	⤷ Sign Up	PRODUCT NAME: LENVATINIB, ELLER ET FARMAKOLOGISK ACCEPTABELT SALT DERAF ELLER ET HYDRAT, HERUNDER LEVATINIB MESILAT; REG. NO/DATE: EU/1/15/1002/001-002 20150601
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.